|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Uemura N, Okamoto S, Yamamoto S, Matsumura
N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N and Schlemper RJ:
Helicobacter pylori infection and the development of gastric
cancer. N Engl J Med. 345:784–789. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu WK, Cho CH, Lee CW, Fan D, Wu K, Yu J
and Sung JJ: Dysregulation of cellular signaling in gastric cancer.
Cancer Lett. 295:144–153. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shen J, Xiao Z, Wu WK, Wang MH, To KF,
Chen Y, Yang W, Li MS, Shin VY, Tong JH, et al: Epigenetic
silencing of miR-490-3p reactivates the chromatin remodeler SMARCD1
to promote Helicobacter pylori-induced gastric carcinogenesis.
Cancer Res. 75:754–765. 2015. View Article : Google Scholar
|
|
5
|
Fukase K, Kato M, Kikuchi S, Inoue K,
Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S and Asaka M;
Japan Gast Study Group: Effect of eradication of Helicobacter
pylori on incidence of metachronous gastric carcinoma after
endoscopic resection of early gastric cancer: An open-label,
randomised controlled trial. Lancet. 372:392–397. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yong X, Tang B, Li BS, Xie R, Hu CJ, Luo
G, Qin Y, Dong H and Yang SM: Helicobacter pylori virulence factor
CagA promotes tumorigenesis of gastric cancer via multiple
signaling pathways. Cell Commun Signal. 13:302015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hayashi T, Senda M, Morohashi H, Higashi
H, Horio M, Kashiba Y, Nagase L, Sasaya D, Shimizu T, Venugopalan
N, et al: Tertiary structure-function analysis reveals the
pathogenic signaling potentiation mechanism of Helicobacter pylori
oncogenic effector CagA. Cell Host Microbe. 12:20–33. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ohnishi N, Yuasa H, Tanaka S, Sawa H,
Miura M, Matsui A, Higashi H, Musashi M, Iwabuchi K, Suzuki M, et
al: Transgenic expression of Helicobacter pylori CagA induces
gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl
Acad Sci USA. 105:1003–1008. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Suzuki M, Mimuro H, Kiga K, Fukumatsu M,
Ishijima N, Morikawa H, Nagai S, Koyasu S, Gilman RH, Kersulyte D,
et al: Helicobacter pylori CagA phosphorylation-independent
function in epithelial proliferation and inflammation. Cell Host
Microbe. 5:23–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tabassam FH, Graham DY and Yamaoka Y:
Helicobacter pylori activate epidermal growth factor receptor- and
phos-phatidylinositol 3-OH kinase-dependent Akt and glycogen
synthase kinase 3beta phosphorylation. Cell Microbiol. 11:70–82.
2009. View Article : Google Scholar
|
|
11
|
Sokolova O, Vieth M, Gnad T, Bozko PM and
Naumann M: Helicobacter pylori promotes eukaryotic protein
translation by activating phosphatidylinositol 3 kinase/mTOR. Int J
Biochem Cell Biol. 55:157–163. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Franco AT, Israel DA, Washington MK,
Krishna U, Fox JG, Rogers AB, Neish AS, Collier-Hyams L,
Perez-Perez GI, Hatakeyama M, et al: Activation of beta-catenin by
carcinogenic Helicobacter pylori. Proc Natl Acad Sci USA.
102:10646–10651. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bronte-Tinkew DM, Terebiznik M, Franco A,
Ang M, Ahn D, Mimuro H, Sasakawa C, Ropeleski MJ, Peek RM Jr and
Jones NL: Helicobacter pylori cytotoxin-associated gene A activates
the signal transducer and activator of transcription 3 pathway in
vitro and in vivo. Cancer Res. 69:632–639. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wei J, Noto J, Zaika E, Romero-Gallo J,
Correa P, El-Rifai W, Peek RM and Zaika A: Pathogenic bacterium
Helicobacter pylori alters the expression profile of p53 protein
isoforms and p53 response to cellular stresses. Proc Natl Acad Sci
USA. 109:E2543–E2550. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wei J, Noto JM, Zaika E, Romero-Gallo J,
Piazuelo MB, Schneider B, El-Rifai W, Correa P, Peek RM and Zaika
AI: Bacterial CagA protein induces degradation of p53 protein in a
p14ARF-dependent manner. Gut. 64:1040–1048. 2015. View Article : Google Scholar :
|
|
16
|
Abu-Elmagd M, Garcia-Morales C and Wheeler
GN: Frizzled7 mediates canonical Wnt signaling in neural crest
induction. Dev Biol. 298:285–298. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Asad M, Wong MK, Tan TZ, Choolani M, Low
J, Mori S, Virshup D, Thiery JP and Huang RY: FZD7 drives in vitro
aggressiveness in Stem-A subtype of ovarian cancer via regulation
of non-canonical Wnt/PCP pathway. Cell Death Dis. 5:e13462014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu R, Zeng S, Xie W, Sun C, Chen YL, Chen
MJ and Zhang L: The expression and function of Frizzled-7 in human
renal cell carcinoma. Clin Transl Oncol. Aug 5–2015.(Epub ahead of
print). http://dx.doi.org/10.1007/s12094-015-1362-3.
|
|
19
|
Deng B, Zhang S, Miao Y, Zhang Y, Wen F
and Guo K: Down-regulation of Frizzled-7 expression inhibits
migration, invasion, and epithelial-mesenchymal transition of
cervical cancer cell lines. Med Oncol. 32:1022015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Simmons GE Jr, Pandey S,
Nedeljkovic-Kurepa A, Saxena M, Wang A and Pruitt K: Frizzled 7
expression is positively regulated by SIRT1 and β-catenin in breast
cancer cells. PLoS One. 9:e988612014. View Article : Google Scholar
|
|
21
|
Ueno K, Hazama S, Mitomori S, Nishioka M,
Suehiro Y, Hirata H, Oka M, Imai K, Dahiya R and Hinoda Y:
Down-regulation of frizzled-7 expression decreases survival,
invasion and metastatic capabilities of colon cancer cells. Br J
Cancer. 101:1374–1381. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Merle P, Kim M, Herrmann M, Gupte A,
Lefrançois L, Califano S, Trépo C, Tanaka S, Vitvitski L, de la
Monte S, et al: Oncogenic role of the frizzled-7/beta-catenin
pathway in hepato-cellular carcinoma. J Hepatol. 43:854–862. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
White BD, Chien AJ and Dawson DW:
Dysregulation of Wnt/β-catenin signaling in gastrointestinal
cancers. Gastroenterology. 142:219–232. 2012. View Article : Google Scholar :
|
|
24
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity: microRNA biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dalmay T and Edwards DR: MicroRNAs and the
hallmarks of cancer. Oncogene. 25:6170–6175. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chiyomaru T, Seki N, Inoguchi S, Ishihara
T, Mataki H, Matsushita R, Goto Y, Nishikawa R, Tatarano S, Itesako
T, et al: Dual regulation of receptor tyrosine kinase genes EGFR
and c-Met by the tumor-suppressive microRNA-23b/27b cluster in
bladder cancer. Int J Oncol. 46:487–496. 2015.
|
|
29
|
Jiang J, Lv X, Fan L, Huang G, Zhan Y,
Wang M and Lu H: MicroRNA-27b suppresses growth and invasion of
NSCLC cells by targeting Sp1. Tumour Biol. 35:10019–10023. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang C, Chen X, Alattar M, Wei J and Liu
H: MicroRNAs in tumorigenesis, metastasis, diagnosis and prognosis
of gastric cancer. Cancer Gene Ther. 22:291–301. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hatakeyama M: Oncogenic mechanisms of the
Helicobacter pylori CagA protein. Nat Rev Cancer. 4:688–694. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Merle P, de la Monte S, Kim M, Herrmann M,
Tanaka S, Von Dem Bussche A, Kew MC, Trepo C and Wands JR:
Functional consequences of frizzled-7 receptor overexpression in
human hepatocellular carcinoma. Gastroenterology. 127:1110–1122.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim M, Lee HC, Tsedensodnom O, Hartley R,
Lim YS, Yu E, Merle P and Wands JR: Functional interaction between
Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin
signaling pathway in hepatocellular carcinoma cells. J Hepatol.
48:780–791. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nambotin SB, Lefrancois L, Sainsily X,
Berthillon P, Kim M, Wands JR, Chevallier M, Jalinot P, Scoazec JY,
Trepo C, et al: Pharmacological inhibition of Frizzled-7 displays
anti-tumor properties in hepatocellular carcinoma. J Hepatol.
54:288–299. 2011. View Article : Google Scholar
|
|
35
|
Ueno K, Hiura M, Suehiro Y, Hazama S,
Hirata H, Oka M, Imai K, Dahiya R and Hinoda Y: Frizzled-7 as a
potential therapeutic target in colorectal cancer. Neoplasia.
10:697–705. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan
YC, Deng X, Chen L, Kim CC, Lau S, et al: FZD7 has a critical role
in cell proliferation in triple negative breast cancer. Oncogene.
30:4437–4446. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kirikoshi H, Sekihara H and Katoh M:
Up-regulation of Frizzled-7 (FZD7) in human gastric cancer. Int J
Oncol. 19:111–115. 2001.PubMed/NCBI
|
|
38
|
Schmuck R, Warneke V, Behrens HM, Simon E,
Weichert W and Röcken C: Genotypic and phenotypic characterization
of side population of gastric cancer cell lines. Am J Pathol.
178:1792–1804. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
King TD, Zhang W, Suto MJ and Li Y:
Frizzled7 as an emerging target for cancer therapy. Cell Signal.
24:846–851. 2012. View Article : Google Scholar :
|
|
40
|
Zhang H, Hao Y, Yang J, Zhou Y, Li J, Yin
S, Sun C, Ma M, Huang Y and Xi JJ: Genome-wide functional screening
of miR-23b as a pleiotropic modulator suppressing cancer
metastasis. Nat Commun. 2:5542011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen Z, Ma T, Huang C, Zhang L, Lv X, Xu
T, Hu T and Li J: miR-27a modulates the MDR1/P-glycoprotein
expression by inhibiting FZD7/β-catenin pathway in hepatocellular
carcinoma cells. Cell Signal. 25:2693–2701. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Song J, Gao L, Yang G, Tang S, Xie H, Wang
Y, Wang J, Zhang Y, Jin J, Gou Y, et al: miR-199a regulates cell
proliferation and survival by targeting FZD7. PLoS One.
9:e1100742014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Deng B, Zhang Y, Zhang S, Wen F, Miao Y
and Guo K: Micro-RNA-142-3p inhibits cell proliferation and
invasion of cervical cancer cells by targeting FZD7. Tumour Biol.
36:8065–8073. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li Z, Chen P, Su R, Li Y, Hu C, Wang Y,
Arnovitz S, He M, Gurbuxani S, Zuo Z, et al: Overexpression and
knockout of miR-126 both promote leukemogenesis. Blood.
126:2005–2015. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ye J, Wu X, Wu D, Wu P, Ni C, Zhang Z,
Chen Z, Qiu F, Xu J and Huang J: miRNA-27b targets vascular
endothelial growth factor C to inhibit tumor progression and
angiogenesis in colorectal cancer. PLoS One. 8:e606872013.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wan L, Zhang L, Fan K and Wang J: miR-27b
targets LIMK1 to inhibit growth and invasion of NSCLC cells. Mol
Cell Biochem. 390:85–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang B, Li D, Kovalchuk A, Litvinov D and
Kovalchuk O: Ionizing radiation-inducible miR-27b suppresses
leukemia proliferation via targeting cyclin A2. Int J Radiat Oncol
Biol Phys. 90:53–62. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Takahashi RU, Miyazaki H, Takeshita F,
Yamamoto Y, Minoura K, Ono M, Kodaira M, Tamura K, Mori M and
Ochiya T: Loss of microRNA-27b contributes to breast cancer stem
cell generation by activating ENPP1. Nat Commun. 6:73182015.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Goto Y, Kojima S, Nishikawa R, Enokida H,
Chiyomaru T, Kinoshita T, Nakagawa M, Naya Y, Ichikawa T and Seki
N: The microRNA-23b/27b/24-1 cluster is a disease progression
marker and tumor suppressor in prostate cancer. Oncotarget.
5:7748–7759. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mu W, Hu C, Zhang H, Qu Z, Cen J, Qiu Z,
Li C, Ren H, Li Y, He X, et al: miR-27b synergizes with anticancer
drugs via p53 activation and CYP1B1 suppression. Cell Res.
25:477–495. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Veliceasa D, Biyashev D, Qin G, Misener S,
Mackie AR, Kishore R and Volpert OV: Therapeutic manipulation of
angiogenesis with miR-27b. Vasc Cell. 7:62015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang YW, Chen X, Gao JW, Zhang H, Ma RR,
Gao ZH and Gao P: High expression of cAMP-responsive
element-binding protein 1 (CREB1) is associated with metastasis,
tumor stage and poor outcome in gastric cancer. Oncotarget.
6:10646–10657. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sokolova O, Bozko PM and Naumann M:
Helicobacter pylori suppresses glycogen synthase kinase 3beta to
promote beta-catenin activity. J Biol Chem. 283:29367–29374. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Gnad T, Feoktistova M, Leverkus M,
Lendeckel U and Naumann M: Helicobacter pylori-induced activation
of beta-catenin involves low density lipoprotein receptor-related
protein 6 and Dishevelled. Mol Cancer. 9:312010. View Article : Google Scholar : PubMed/NCBI
|
